Literature DB >> 8067770

Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

J Beyer1, S Schwartz, V Heinemann, W Siegert.   

Abstract

Entities:  

Mesh：

Year:  1994        PMID： 8067770      PMCID： PMC188126          DOI： 10.1128/AAC.38.5.911

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


× No keyword cloud information.
  104 in total

1.  The compromised host as sentinel chicken.

Authors:  R H Rubin
Journal:  N Engl J Med       Date:  1987-10-29       Impact factor: 91.245

2.  Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients.

Authors:  R J Sherertz; A Belani; B S Kramer; G J Elfenbein; R S Weiner; M L Sullivan; R G Thomas; G P Samsa
Journal:  Am J Med       Date:  1987-10       Impact factor: 4.965

3.  Efficacy of fluconazole (UK-49,858) against experimental aspergillosis and cryptococcosis in mice.

Authors:  P F Troke; R J Andrews; M S Marriott; K Richardson
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

4.  Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.

Authors:  G Tricot; E Joosten; M A Boogaerts; J Vande Pitte; G Cauwenbergh
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

Review 5.  Activity of orally, topically, and parenterally administered itraconazole in the treatment of superficial and deep mycoses: animal models.

Authors:  J Van Cutsem; F Van Gerven; P A Janssen
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

6.  Itraconazole in the treatment of human mycoses: review of three years of clinical experience.

Authors:  G Cauwenbergh; P De Doncker; K Stoops; A M De Dier; H Goyvaerts; V Schuermans
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb

7.  Primary cutaneous aspergillosis associated with Hickman intravenous catheters.

Authors:  M D Allo; J Miller; T Townsend; C Tan
Journal:  N Engl J Med       Date:  1987-10-29       Impact factor: 91.245

8.  Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients.

Authors:  V Fainstein; G P Bodey; L Elting; A Maksymiuk; M Keating; K B McCredie
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

Review 9.  Prevention and mycoses in immunocompromised patients.

Authors:  F Meunier
Journal:  Rev Infect Dis       Date:  1987 Mar-Apr

10.  Aspergillus sinusitis in cancer patients.

Authors:  A F Viollier; D E Peterson; C A De Jongh; K A Newman; W C Gray; J C Sutherland; M A Moody; S C Schimpff
Journal:  Cancer       Date:  1986-07-15       Impact factor: 6.860
View more
  11 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

Review 2.  Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.

Authors:  A J Coukell; R N Brogden
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

3.  Multicentric epidemiological study of Aspergillus fumigatus isolates by multilocus enzyme electrophoresis.

Authors:  E Rodriguez; T De Meeüs; M Mallie; F Renaud; F Symoens; P Mondon; M A Piens; B Lebeau; M A Viviani; R Grillot; N Nolard; F Chapuis; A M Tortorano; J M Bastide
Journal:  J Clin Microbiol       Date:  1996-10       Impact factor: 5.948

Review 4.  Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae--a review.

Authors:  N D Lees; B Skaggs; D R Kirsch; M Bard
Journal:  Lipids       Date:  1995-03       Impact factor: 1.880

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

6.  Studies of in vitro activities of voriconazole and itraconazole against Aspergillus hyphae using viability staining.

Authors:  C Lass-Flörl; M Nagl; C Speth; H Ulmer; M P Dierich; R Würzner
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Risk factors for systemic fungal infections in liver transplant recipients.

Authors:  J Briegel; H Forst; B Spill; A Haas; B Grabein; M Haller; E Kilger; K W Jauch; K Maag; G Ruckdeschel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

8.  Aerosol amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in neutropenic cancer patients.

Authors:  G F Behre; S Schwartz; K Lenz; W D Ludwig; H Wandt; E Schilling; V Heinemann; H Link; A Trittin; O Boenisch
Journal:  Ann Hematol       Date:  1995-12       Impact factor: 3.673

Review 9.  Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis.

Authors:  R N Brogden; K L Goa; A J Coukell
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

10.  Comparison of three typing methods for clinical and environmental isolates of Aspergillus fumigatus.

Authors:  D Lin; P F Lehmann; B H Hamory; A A Padhye; E Durry; R W Pinner; B A Lasker
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.